Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
May 22, 2023	Filing of certain prospectuses and communications in connection with business combination transactions	425	Other	0001104659-23-062925.pdf 0001104659-23-062925.rtf 0001104659-23-062925.xls View HTML
May 22, 2023	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001104659-23-062928.pdf 0001104659-23-062928.rtf 0001104659-23-062928.xls View HTML
May 22, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0001104659-23-062923.pdf 0001104659-23-062923.rtf 0001104659-23-062923.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 15, 2023	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-23-029527.pdf 0001209191-23-029527.rtf 0001209191-23-029527.xls View HTML
May 11, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0000950170-23-020817.pdf 0000950170-23-020817.rtf 0000950170-23-020817.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT View HTML
May 11, 2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0000950170-23-020832.pdf 0000950170-23-020832.rtf 0000950170-23-020832.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT View HTML
May 10, 2023	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-23-028565.pdf 0001209191-23-028565.rtf 0001209191-23-028565.xls View HTML
May 05, 2023	An amendment to the SC 13G filing	SC 13G/A	Other	0001214659-23-006567.pdf 0001214659-23-006567.rtf 0001214659-23-006567.xls View HTML
May 05, 2023	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0001209191-23-027832.pdf 0001209191-23-027832.rtf 0001209191-23-027832.xls View HTML
May 05, 2023	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-23-027833.pdf 0001209191-23-027833.rtf 0001209191-23-027833.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.